Dallas, Texas 09/05/2013 (Financialstrend) – August 2013 was a happening month for pharmacy giant, Inovio Pharmaceuticals Inc (NYSEMKT:INO). The company had more to offer investors along with its 2Q2013 results: a Malaria DNA Vaccine. It reported 2.5 times higher net losses, though, its revenue on a-year-on-year comparison had doubled. The announcement of weak results on August 9 has sent INO shares into a slide of over 32% in the past 30 days. The shares were trading at $2.02 at end of business on September 4, 33% lower than the 52 weeks high price of $3.03. Its market capitalization is $383 Million and its 90-day average daily trade volume is 5.9 Million.
Malaria DNA Vaccine
While investors are feeling glittery, old time pharma and bio tech analysts are having a more sanguine view of INO Malaria vaccine tests results on animals. On August 15Inovio announced that its test procedure. It included the use of its patented Syncon vaccine (containing multiple malaria antigens) into small animals and non-human primates through its patented electroporation device called Cellectra. Apparently, the results demonstrated a, “strong and durable antibody and T-cell immune response” in the subject animals. As a consequence of these favourable pre-clinical test results, INO is forging ahead to initiate Phase 1 and 2a clinical trials in 2014.
Immense potential for the Anti Malaria drug
As per WHO report, as of 2010 there were more than 200 Million cases of Malaria reported worldwide. In a world worried, that the current range of vaccines available in the market do not show good results, especially in children in the ‘infant’ group, INO results bode good. If INO results continue to positive and a strong drug is developed, INO will have a relatively competition free market to sell its potential wonder drug. Currently, INO has published its findings in American Society for Microbiology’s journal and has invited peer reviews.